Drug Discovery for Parkinson's With Mutations in the GBA Gene

Sponsor
The New York Stem Cell Foundation (Other)
Overall Status
Recruiting
CT.gov ID
NCT05536388
Collaborator
Silverstein Foundation (Other)
60
1
36
1.7

Study Details

Study Description

Brief Summary

The New York Stem Cell Foundation (NYSCF) is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use.

Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.

Condition or Disease Intervention/Treatment Phase
  • Other: Biological Sample Collection

Detailed Description

Researchers at the New York Stem Cell Foundation (NYSCF) study diverse diseases, conditions, and traits by creating stem cells from biological samples. These "pluripotent" stem cells can become any cell in the human body, including cells that may be difficult, invasive, or impossible to obtain directly.

Additionally, researchers perform genetic testing to learn more about DNA, a material in most cells that contains instructions for the body's development and functions (such as traits like eye color and risk of certain diseases). A piece of DNA that determines the specific role of a cell is called a "gene." If the instructions in a gene are abnormal, this can lead to disease.

Participation in the study involves: (1) completion of health questionnaires, (2) providing a skin and/or blood sample from which stem cells may be created, (3) collection of a saliva sample for genetic analysis, and (4) possible future follow-up to provide additional information or learn about other research studies.

This study is not a clinical trial.

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Drug Discovery for Parkinson's With Mutations in the GBA Gene
Actual Study Start Date :
Jul 15, 2022
Anticipated Primary Completion Date :
Jul 15, 2025
Anticipated Study Completion Date :
Jul 15, 2025

Arms and Interventions

Arm Intervention/Treatment
Parkinson's Disease

Subjects in this group will have a diagnosis of Parkinson's disease with or without a known GBA gene mutation.

Other: Biological Sample Collection
Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)
Other Names:
  • Biological sample collection for biobanking and research
  • Gaucher Disease

    Subjects in this group with have a diagnosis of Gaucher disease with or without a known GBA gene mutation.

    Other: Biological Sample Collection
    Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)
    Other Names:
  • Biological sample collection for biobanking and research
  • Healthy Control

    Subjects in this group will serve as healthy controls.

    Other: Biological Sample Collection
    Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)
    Other Names:
  • Biological sample collection for biobanking and research
  • Outcome Measures

    Primary Outcome Measures

    1. Establishment of a diverse bank of biological samples, stem cell lines, derivatives, and associated information. [Baseline]

      Establish a robust disease signature using a cohort of PD and carefully matched control samples to screen a library of approximately 3,000 compounds to determine whether any compounds improve or reverse disease phenotypes.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age 18 years or older.

    • Diagnosis of Parkinson's disease, Gaucher disease, or healthy control.

    • Must provide written informed consent unless physical limitations preclude signing.

    Exclusion Criteria:
    • For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.

    • For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection.

    • For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The New York Stem Cell Foundation New York New York United States 10019

    Sponsors and Collaborators

    • The New York Stem Cell Foundation
    • Silverstein Foundation

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The New York Stem Cell Foundation
    ClinicalTrials.gov Identifier:
    NCT05536388
    Other Study ID Numbers:
    • 10-008
    First Posted:
    Sep 10, 2022
    Last Update Posted:
    Sep 10, 2022
    Last Verified:
    Sep 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by The New York Stem Cell Foundation
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 10, 2022